Metaphore Biotechnologies seeks to mimic nature with $50M for autoimmune, immunology drugs out of Flagship

Kyle LaHucik

Senior Reporter

Flagship Pioneering has churned out another biotech startup that taps into nature’s seemingly endless supply of insights and, like many new life sciences companies, is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Metaphore Biotechnologies seeks to mimic nature with $50M for autoimmune, immunology drugs out of Flagship

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Metaphore Biotech­nolo­gies seeks to mim­ic na­ture with $50M for au­toim­mune, im­munol­o­gy drugs out of Flag­ship

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Metaphore Biotechnologies seeks to mimic nature with $50M for autoimmune, immunology drugs out of Flagship